Home›Stock Screener›Accretion Pharmaceuticals›Quarterly Results

Accretion Pharmaceuticals Quarterly Results for Trading Insights

Latest Quarter Net Profit
₹7 Cr
QMarch 2025
Quarterly Results

In 2026, Accretion Pharmaceuticals (ACCPL) reported revenue ₹0 Cr and net profit ₹0 Cr. Also explore Accretion Pharmaceuticals share price performance to track price trends across different timeframes.

ACCPL Quarterly Results — Revenue, Profit & EPS Highlights

Accretion Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with Accretion Pharmaceuticals valuation methods to assess whether the stock is under or overvalued.

  • Revenue of ₹58 Cr in March 2025 (+0.0% vs March 2025, +346.2% vs March 2024)
  • Net Profit of ₹7 Cr in March 2025 (+0.0% vs March 2025, +250.0% vs March 2024)
  • EBITDA of ₹12 Cr in March 2025 (+0.0% vs March 2025)
  • Operating Margin of 21.0% in March 2025 (+0.0pp vs March 2025)
  • Earnings Per Share of ₹8.48 in March 2025 (+0.0% vs March 2025)

Accretion Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS

ACCPL quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric 2026 March 2025 March 2024 QoQ YoY
Revenue (₹ Cr) 0 58 13 - -
Net Profit (₹ Cr) 0 7 2 - -
EBITDA (₹ Cr) 0 12 3 - -
EPS (₹) 0.00 8.48 1.96 - -
Operating Margin (%) 0.0% 21.0% 19.0% - -

ACCPL Share Price Trend — 1-Year Movement Across Quarterly Results

Accretion Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Accretion Pharmaceuticals stock price NSE.

Profitability Ratios

Profit Margin 12.1%
EBITDA Margin 20.7%
Operating Margin 21.0%
ROE (Annual) 46.7%

Balance Sheet Highlights

Total Assets ₹40 Cr
Total Equity ₹15 Cr
Current Assets ₹34 Cr
Current Liabilities ₹1 Cr

Cash Flow Analysis

Operating Cash Flow ₹6 Cr
Investing Cash Flow ₹-2 Cr
Financing Cash Flow ₹-4 Cr
Net Cash Flow ₹0 Cr

Revenue Trend (₹ Cr)

March 2024 13
March 2025 58
2026 0

Net Profit Trend (₹ Cr)

March 2024 2
March 2025 7
2026 0

Operating Margin Trend (%)

March 2024 19.0%
March 2025 21.0%
2026 0.0%

ACCPL vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Accretion Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Mar 2026 		₹442,581.33 Cr 1844.6 15,018 2,710 +1.0% +11.8% 18.0% 163.2
Divis Laboratories
Sept 2025 		₹179,470.03 Cr 6887.0 2,860 689 +7.1% - 24.1% 265.2
Torrent Pharmaceuti…
Mar 2026 		₹151,833.39 Cr 4486.2 4,111 364 +27.7% +42.2% 8.9% 389.8
Cipla
Mar 2026 		₹113,024.67 Cr 1399.2 6,612 543 -14.3% -4.0% 8.2% 203.7
Dr Reddys Laborator…
Mar 2026 		₹109,104.54 Cr 1307.2 7,996 221 -12.5% -11.5% 2.8% 493.3
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores